201 related articles for article (PubMed ID: 33106475)
1. Genome-wide association studies of antidepressant class response and treatment-resistant depression.
Li QS; Tian C; Hinds D;
Transl Psychiatry; 2020 Oct; 10(1):360. PubMed ID: 33106475
[TBL] [Abstract][Full Text] [Related]
2. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
Li QS; Tian C; Seabrook GR; Drevets WC; Narayan VA
Transl Psychiatry; 2016 Sep; 6(9):e889. PubMed ID: 27622933
[TBL] [Abstract][Full Text] [Related]
3. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
4. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
Edwards SJ; Hamilton V; Nherera L; Trevor N
Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic analysis of 23andMe survey data: Treatment-resistant depression from participants' perspective.
Li QS; Tian C; McIntyre MH; Sun Y; ; Hinds DA; Narayan VA
Psychiatry Res; 2019 Aug; 278():173-179. PubMed ID: 31207454
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
10. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice.
Vijaya Kumar K; Rudra A; Sreedhara MV; Siva Subramani T; Prasad DS; Das ML; Murugesan S; Yadav R; Trivedi RK; Louis JV; Li YW; Bristow LJ; Naidu PS; Vikramadithyan RK
Brain Behav Immun; 2014 Nov; 42():204-11. PubMed ID: 25016199
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
Wade RL; Kindermann SL; Hou Q; Thase ME
J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
[TBL] [Abstract][Full Text] [Related]
14. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
[TBL] [Abstract][Full Text] [Related]
15. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
Kurose K; Hiratsuka K; Ishiwata K; Nishikawa J; Nonen S; Azuma J; Kato M; Wakeno M; Okugawa G; Kinoshita T; Kurosawa T; Hasegawa R; Saito Y
Psychiatry Res; 2012 Aug; 198(3):424-9. PubMed ID: 22445761
[TBL] [Abstract][Full Text] [Related]
17. Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Lee CW; Chen YJ; Wu HF; Chung YJ; Lee YC; Li CT; Lin HC
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():102-113. PubMed ID: 30940482
[TBL] [Abstract][Full Text] [Related]
18. [Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey].
Spadone C; Sylvestre M; Chiarelli P; Richard-Berthe C
Encephale; 2005; 31(6 Pt 1):698-704. PubMed ID: 16462689
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA.
Miller M; Pate V; Swanson SA; Azrael D; White A; Stürmer T
CNS Drugs; 2014 Jan; 28(1):79-88. PubMed ID: 24146116
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP.
Wigmore EM; Hafferty JD; Hall LS; Howard DM; Clarke TK; Fabbri C; Lewis CM; Uher R; Navrady LB; Adams MJ; Zeng Y; Campbell A; Gibson J; Thomson PA; Hayward C; Smith BH; Hocking LJ; Padmanabhan S; Deary IJ; Porteous DJ; Mors O; Mattheisen M; Nicodemus KK; McIntosh AM
Pharmacogenomics J; 2020 Apr; 20(2):329-341. PubMed ID: 30700811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
